Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
53%
Lung Adenocarcinoma
53%
Tumor
32%
Lung Cancer
23%
T Cells
19%
Tumor Microenvironment
17%
Programmed Death-ligand 1 (PD-L1)
16%
Tumor Cells
16%
Immunohistochemistry
12%
Overall Survival
12%
Multiplex Immunohistochemistry
12%
Metastasis
11%
Adenocarcinoma
11%
Progression-free Survival
11%
Lung
10%
CD73
10%
CD8+
10%
Neoadjuvant
10%
Spatial Transcriptomics
10%
Clinical Outcomes
10%
Triple-negative Breast Cancer
9%
Breast Cancer
9%
Protein Expression
9%
Squamous Cell Carcinoma (SqCC)
8%
Poor Survival
8%
Nivolumab
8%
Non-small Cell Lung Cancer Patients
8%
Pancreatic Ductal Adenocarcinoma
7%
Spatial Analysis
7%
Molecular Features
7%
Phase I Study
7%
Immune Checkpoint Blockade
7%
Putative Drug Targets
7%
Tumor-infiltrating Lymphocytes
7%
Durvalumab
7%
Follicular Lymphoma
7%
KRAS mutant Lung Cancer
7%
Prognostic Significance
7%
Tissue Microarray
7%
Macrophages
6%
Epithelial-to-mesenchymal Transition
6%
Anti-programmed Cell Death Protein 1 (anti-PD-1)
6%
Chimeric Antigen Receptor T Cells (CAR-T)
6%
Cancer Cells
6%
Small Cell Lung Cancer
6%
Programmed Cell Death Protein 1 (PD-1)
6%
Tumor Immunity
6%
CD3+
6%
Ipilimumab
6%
Breast Carcinoma
6%
Immunology and Microbiology
Lung
100%
T Cell
28%
Programmed Death-Ligand 1
19%
Immunocompetent Cell
18%
Overall Survival
16%
Tumor Cell
16%
Immunofluorescence
15%
Immunotherapy
15%
Immune Microenvironment
13%
Phosphotransferase
13%
Kinase
13%
CD3 Antigen
13%
Transcriptomics
13%
B Cell
11%
CD8
10%
Immunosuppressive Drug
10%
Macrophage
9%
Immune Checkpoint Blockade
9%
Immune Checkpoint Inhibitor
9%
Cytotoxic T-Cell
9%
Ribonucleic Acid
9%
Tumor Immunity
8%
T Cell Receptor
7%
Cell Population
7%
Squamous Cell
7%
Arm
7%
Evolution
6%
Protein Expression
6%
Immune Cell Infiltration
6%
Gene Expression
6%
Staining
6%
Myeloid
6%
Tumor-Infiltrating Lymphocytes
5%
Nivolumab
5%
Cell Interaction
5%
Neoadjuvant Immunotherapy
5%
CD68
5%
Recurrence Free Survival
5%
Progression Free Survival
5%
Ipilimumab
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
37%
Lung Adenocarcinoma
29%
Tumor
27%
Neoplasm
21%
Lung
18%
Overall Survival
17%
Diseases
15%
Progression Free Survival
13%
Lung Cancer
13%
Programmed Death-Ligand 1
13%
Adenocarcinoma
11%
Tumor Microenvironment
10%
Immunofluorescence
10%
Genetics
9%
Malignant Neoplasm
9%
Therapeutic Target
8%
Non-Small Cell Lung Cancer
8%
Biological Marker
8%
Clinical Trial
8%
Immunotherapy
8%
Small Cell Lung Cancer
7%
Immune Checkpoint Inhibitor
7%
T Cell
7%
Neuroendocrine Tumor
7%
Epidermal Growth Factor Receptor
7%
Durvalumab
7%
Immunocompetent Cell
7%
Squamous Cell Carcinoma
6%
Breast Carcinoma
6%
Recurrence Free Survival
6%
Pathogenesis
6%
Upregulation
5%
Connective Tissue Cancer
5%
Tumor Infiltrating Lymphocyte
5%
Rare Tumor
5%
Artificial Intelligence
5%
Precursor
5%
Cytotoxic T-Cell
5%
Tissue Microarray
5%